Details of the Drug

General Information of Drug (ID: DMAFPNI)

Drug Name

AZD0780

Indication

Disease Entry	ICD 11	Status	REF
Elevated Lipoprotein(a)	5C80.1	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Proprotein convertase subtilisin/kexin type 9 (PCSK9)	TTBRG7E	PCSK9_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Elevated Lipoprotein(a)

ICD Disease Classification

5C80.1

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Proprotein convertase subtilisin/kexin type 9 (PCSK9)	DTT	PCSK9	4.82E-02	-0.07	-0.3

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05384262) A Phase I, Randomized, Single-Blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 Following Single and Multiple Ascending Dose Administration to Healthy Subjects With or Without Elevated LDL-C Levels. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of AstraZeneca